These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33410246)

  • 1. Statistical inferences on nonconstant relative potency with quantal response data.
    Kerns LX
    Biom J; 2021 Apr; 63(4):825-840. PubMed ID: 33410246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplicity-Adjusted Confidence Limits in Risk Assessment with Quantal Response Data.
    Kerns L
    J Biopharm Stat; 2018; 28(6):1182-1192. PubMed ID: 29543575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous confidence bands for log-logistic regression with applications in risk assessment.
    Kerns LX
    Biom J; 2017 May; 59(3):420-429. PubMed ID: 28128855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parameterizing dose-response models to estimate relative potency functions directly.
    Dinse GE; Umbach DM
    Toxicol Sci; 2012 Oct; 129(2):447-55. PubMed ID: 22700543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing non-constant relative potency.
    Dinse GE; Umbach DM
    Regul Toxicol Pharmacol; 2011 Aug; 60(3):342-53. PubMed ID: 21601607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplicity-adjusted inferences in risk assessment: benchmark analysis with quantal response data.
    Nitcheva DK; Piegorsch WW; West RW; Kodell RL
    Biometrics; 2005 Mar; 61(1):277-86. PubMed ID: 15737104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Model and inference for quantal response pharmacological assay].
    Kawai N; Goto M
    Nihon Yakurigaku Zasshi; 2000 Jul; 116(1):29-35. PubMed ID: 10976450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability.
    Lalonde RL; Ouellet D; Kimanani EK; Potvin D; Vaughan LM; Hill MR
    J Pharmacokinet Biopharm; 1999 Feb; 27(1):67-83. PubMed ID: 10533698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benchmark dose risk analysis with mixed-factor quantal data in environmental risk assessment.
    Sans-Fuentes MA; Piegorsch WW
    Environmetrics; 2021 Aug; 32(5):. PubMed ID: 34354387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A curve similarity approach to parallelism testing in bioassay.
    Faya P; Rauk AP; Griffiths KL; Parekh B
    J Biopharm Stat; 2020 Jul; 30(4):721-733. PubMed ID: 32163316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a statistical outlier in potency bioassays.
    Sondag P; Zeng L; Yu B; Rousseau R; Boulanger B; Yang H; Novick S
    Pharm Stat; 2018 Nov; 17(6):701-709. PubMed ID: 30112804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous Confidence Bands for Abbott-Adjusted Quantal Response Models.
    Buckley BE; Piegorsch WW
    Stat Methodol; 2008 May; 5(3):209-219. PubMed ID: 19412325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing for parallelism in the heteroscedastic four-parameter logistic model.
    Sidik K; Jonkman JN
    J Biopharm Stat; 2016; 26(2):250-68. PubMed ID: 25629201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A generalized response surface model with varying relative potency for assessing drug interaction.
    Kong M; Lee JJ
    Biometrics; 2006 Dec; 62(4):986-95. PubMed ID: 17156272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A method for bioassay of potency and effectiveness of inhaled bronchodilators in normal subjects.
    Foster RW; Atanga GK; Carpenter JR; Evans DE; Rakshi K; Small RC
    Br J Clin Pharmacol; 1991 Apr; 31(4):445-55. PubMed ID: 2049254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin sensitization testing in potency and risk assessment.
    Kimber I; Basketter DA; Berthold K; Butler M; Garrigue JL; Lea L; Newsome C; Roggeband R; Steiling W; Stropp G; Waterman S; Wiemann C
    Toxicol Sci; 2001 Feb; 59(2):198-208. PubMed ID: 11158712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confidence bands for low-dose risk estimation with quantal response data.
    Al-Saidy OM; Piegorsch WW; West RW; Nitcheva DK
    Biometrics; 2003 Dec; 59(4):1056-62. PubMed ID: 14969485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing drug additivity based on monotherapies.
    Yang H; Novick SJ; Zhao W
    Pharm Stat; 2015; 14(4):332-40. PubMed ID: 25962689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing Monte Carlo error in the Bayesian estimation of risk ratios using log-binomial regression models.
    Salmerón D; Cano JA; Chirlaque MD
    Stat Med; 2015 Aug; 34(19):2755-67. PubMed ID: 25944082
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.